Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - Reshaping the role of India's pharmaceutical CFOs

This article was originally published in Scrip

Executive Summary

The $12 billion Indian pharmaceutical industry is in the throes of tumultuous change characterised by high growth both in domestic and international business. While Indian generic companies are establishing themselves as significant players in the highly competitive but fast-growing global generics market, in both the regulated and semi-regulated markets, the domestic pharmaceutical industry is predicted to double its size from the current $7.8 billion over the next five years. This growth is driven by the healthcare boom riding on increasing health awareness, a highly under-serviced rural market, the burgeoning middle-class and emerging critical enablers in the form of health insurance. Another significant development is the increasing ambition of Indian players to develop capabilities in basic research, which requires significant investment and is fraught with risk.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts